Intraday Info: Luminex Corporation (NASDAQ:LMNX) locked on 27/01/2017 at $20.07. It has average volume 153,350 whilst it totals volume 99,115. The company has EPS 0.87 and according to analysts next quarter EPS and next year estimate EPS will 0.09 and 0.51 respectively. Profit Margin of LMNX 14.50% and it total income 37.60 million.
Ownership Summary: Luminex Corporation has total institutional ownership 79.59% while its total outstanding shares 44 millions that’s value of holdings $696 million.
Active Positions: In the latest year, LMNX 75 holders have raised its positions while it contains total 2,641,033 shares. And the strength of reduced positions holders and held positions holders are 87 and 29 respectively.
New and Sold Out Positions: In LMNX force of new positions holders 12 and it has total shares 449,837. And force of sold out positions holders 21 and it has 460,099 shares.
Comparison with Other Company: The Market Value of LMNX is $874,751 below from Boston Scientific Corporation market value which is $32M. Current Last Sale of LMNX is $20.07 below from BSX current last sale which is $23.87.
Luminex Corporation declared that it has obtained FDA clearance for the ARIES® institution B Streptococcus (GBS) Assay for antepartum detection of GBS colonization in pregnant women. that is the 0.33 assay the FDA has cleared to be used at the Luminex ARIES® systems. The organisation has additionally executed CE-IVD marking for the ARIES® GBS Assay.
Contamination with group B Streptococcus (GBS), also referred to as Streptococcus agalactiae, is a leading cause of neonatal morbidity and mortality, inflicting meningitis, pneumonia and septicemia in newborns and their moms. One in four pregnant women are colonized with GBS, with most no longer exhibiting signs and symptoms; but, it is able to be transmitted to the newborn throughout shipping. If no longer treated, GBS can result in infection or even loss of life within the first week of a newborn’s existence. The centers for sickness manage and Prevention recommends familiar GBS testing of ladies of their thirty fifth-37th week of being pregnant.
The ARIES® GBS Assay is a actual-time polymerase chain response (PCR) based qualitative in vitro diagnostic take a look at designed to hit upon institution B Streptococcus nucleic acid from 18-24 hour Lim broth enriched vaginal-rectal swab specimens acquired from pregnant ladies. It gives higher sensitivity and raised accuracy while comparison to tradition, and a discounted turnaround time of two hours after enrichment, assessment to 48 hours for way of life, with simultaneous STAT and batch checking out at the sample to answer ARIES® systems.